EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Toll-like receptor 1/2 activation reduces immunoglobulin free light chain production by multiple myeloma cells in the context of bone marrow stromal cells and fibronectin

Jahan Abdi iD, Frank Redegeld

PLOS ONE · 2025

DOI: 10.1371/journal.pone.0310395 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS ONE, 2025. Verfasst von Jahan Abdi und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Science, CHHSN, California State University Dominguez Hills, Carson, California, United States of America. Hauptthemen laut MEDLINE: Multiple Myeloma, Toll-Like Receptor 2, Fibronectins, Toll-Like Receptor 1. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Toll-like receptor (TLRs) activation in multiple myeloma (MM) cells induces heterogeneous functional responses including cell growth and proliferation, survival or apoptosis. These effects have been suggested to be partly due to increase in secretion of cytokines such as IL-6 or IFNα among others from MM cells following TLR activation. However, whether triggering of these receptors also modulates production of immunoglobulin free light chains (FLCs), which largely contribute to MM pathology, has not been investigated in MM cells before. This study explored the effect of TLR1/2 ligand (Pam3CSK4) alone or combined with bortezomib (BTZ) on production of FLCs in human myeloma cell lines, L363, OPM-2, U266 and NCI-H929. It also investigated the above effect when MM cells were exposed to bone marrow stromal cells (BMSCs) or fibronectin (FN). Adhesion to BMSCs or FN increased secretion of FLC in MM cells. Pam3CSK4 decreased FLC production, and this effect was enhanced in combination with BTZ but attenuated when MM cells adhered to BMSCs or FN. The findings of this study imply that activation of TLR1/2 downregulates FLC production in MM cells even in the context of bone marrow microenvironment components and suggest that targeting some TLRs such as TLR1/2 might have therapeutic potential.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaToll-Like Receptor 2FibronectinsToll-Like Receptor 1Immunoglobulin Light ChainsMesenchymal Stem CellsHumansCell Line, TumorBortezomibLipopeptidesCell Adhesion

Substanzen

Toll-Like Receptor 2FibronectinsBortezomibToll-Like Receptor 1Immunoglobulin Light ChainsPam(3)CSK(4) peptideLipopeptidesTLR2 protein, humanTLR1 protein, human

Autor:innen und Institutionen

  • Department of Clinical Science, CHHSN, California State University Dominguez Hills, Carson, California, United States of America.
  • Division of Pharmacology, Department of Pharmaceutical Sciences, Faculty of Science, Utrecht University, Utrecht, The Netherlands.

ORCID-Profile: Jahan Abdi

Zitieren

APA

Abdi, J., & Redegeld, F. (2025). Toll-like receptor 1/2 activation reduces immunoglobulin free light chain production by multiple myeloma cells in the context of bone marrow stromal cells and fibronectin. PLOS ONE. https://doi.org/10.1371/journal.pone.0310395

Vancouver

Abdi J, Redegeld F. Toll-like receptor 1/2 activation reduces immunoglobulin free light chain production by multiple myeloma cells in the context of bone marrow stromal cells and fibronectin. PLOS ONE. 2025. doi:10.1371/journal.pone.0310395

BibTeX
@article{Abdi2025,
  author = {Abdi, Jahan and Redegeld, Frank},
  title = {Toll-like receptor 1/2 activation reduces immunoglobulin free light chain production by multiple myeloma cells in the context of bone marrow stromal cells and fibronectin},
  journal = {PLOS ONE},
  year = {2025},
  doi = {10.1371/journal.pone.0310395}
}
Kostenlos starten →